LTGO (LTGO) Stock Analysis

$23.040

+0.574 (+2.49%)At close

Loading chart…

High: 23.570
Open: 22.680
VWAP: 22.88
Vol: 227.44K
Mkt Cap: —
Low: 22.020
Amount: 5.20M
EV/EBITDA, TTM: 0.00

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its two product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors designed to inhibit the transmission of pain. It is also advancing additional Nav1.8 candidates that can address alternative formulation and delivery approaches. The Company's lead product candidate, LTG-001, is an oral Nav1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain. LTG-321 is its next-generation candidate for the inhibition of Nav1.8, being developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis (OA). LTG-001 and LTG-321 are in clinical development, and LTG-418 and the Company's other product candidates and programs are in preclinical development or discovery stages.

AI analysis of LTGO (LTGO)

hold

Latigo Biotherapeutics, Inc. is currently not a strong buy due to its negative fundamentals and recent price volatility. The current price is $24.23, which is down 3.08% from yesterday, and the forward P/E ratio is 0, indicating uncertainty in future earnings. Although the stock has gained 34.61% year-to-date, the lack of positive catalysts and a negative P/E ratio of -36.00 suggest caution. The main risk is the negative price-to-book ratio of -6.26, indicating potential issues with asset valuation.